DIABETES
Why are doctors not moving to second-generation basal insulins?
- Cost: Free of charge
- CPD Points: 1 General CEU
- Retries: 3 attempts
- CPD Accredited in South Africa
- Free certification
- Access on desktop, tablet and mobile
- Access from anywhere
- No time limits, work at your own pace
In this practical 30-minute clinical discussion, host Dr Brad Merwitz and well-known teacher and clinician, Dr Isaac Mashitisho, explore how barriers to the use of improved basal insulins can be overcome.
About our experts
Dr Brad Merwitz
Physician & Endocrinologist
Wits Donald Gordon Medical Centre.
Netcare Milpark Hospital Johannesburg
Dr Brad Merwitz is a specialist physician and endocrinologist with a special interest in diabetes mellitus (especially Type 2), osteoporosis, cardiovascular risk management, lipidology and general endocrinology. In addition, Dr Merwitz has an interest in novel approaches to metabolic well-being including exercise strategies, intermittent fasting and cold exposure.
Since March 2017 Dr Merwitz has been working as an endocrinologist in private practice at Netcare Milpark Hospital and the Mediclinic Wits Donald Gordon Medical Centre.
Mediclinic Legae
Mabopane
Gauteng
Dr Mashitisho is a highly esteemed healthcare practitioner specialising in Internal Medicine, with a distinguished career currently based at Mediclinic Legae. Dr Mashitisho's commitment to excellence and dedication to patient care have made him a trusted figure in the medical community.
With a wealth of experience and a passion for improving patient outcomes, Dr Lesiba Mashitisho continues to make a significant impact in the field of Internal Medicine, earning the respect and admiration of colleagues and patients alike.
Learning objectives
- To establish the importance of glucose control over time to reduce microvascular and macrovascular complications
- To encourage the use of continuous glucose monitoring (CGM), even for briefer periods of time (3/4 days) to assess time-in-range and glucose variability more accurately in an individual patient
- To ensure that both T2DM and T1DM patients receive the best basal insulin with comprehensive 24-hour coverage and a reduced incidence of hypoglycaemia, particularly at night.
